Experts debate whether melatonin is actually a hormone. A common misconception is that the pineal gland is the only source of melatonin production. The pineal gland is not actually an endocrine gland. It is specialized nervous system tissue. Over the course of evolution it has lost the capacity to respond directly to light stimulation. It has developed the function of intermediary in our adaptation to day-night periodicity via neural impulses from the retina. Melatonin is synthesized at multiple sites in the body. It is produced in the intestinal wall lining cells in much greater quantity than in the pineal. It is produced by components of our white blood cell system as well.
After the pineal is removed, melatonin is still produced at other sites. There is no central “releasing factor” for melatonin, as in the case with other hormones. Melatonin is a universal chemical mediator in the plant and animal world. It is not a species-specific molecule. This debate has fascinating implications for the scientists who study the subject. From a practical point of view melatonin is safe and can be very beneficial for the appropriate person. A reduction in melatonin production or an alteration of the normal circadian pattern of secretion is not an inevitable consequence of aging. Not all people need or will benefit from melatonin supplementation. The need for supplementation, the route of supplementation and the dose needs to be individualized, monitored and adjusted.
Association of Melatonin deficiency and Illness:
Recent advances in the knowledge of psychoneuroimmunology have demonstrated that anticancer immunity is under neuroendocrine control and that melatonin may stimulate IL-2-dependent anticancer activity. Experimental manipulations activating the pineal gland, or the administration of melatonin, reduce the incidence and growth rate of chemically induced murine mammary tumors, while pinealectomy, or situations which cause a reduction of melatonin production usually stimulate mammary carcinogenesis. The direct actions of melatonin on mammary tumors have been suggested because of its ability to inhibit, at physiological doses, the in vitro proliferation of MCF-7 human breast cancer cells. There are studies in the literature suggesting similar benefit for other solid tumors and hematologic malignancies. This does not mean that taking melatonin will prevent cancer or treat cancer. It is preliminary research that is interesting and suggestive. In appropriate patients, with low levels of melatonin, supplementation may be helpful. When dosed correctly it will not be harmful.
Melatonin may be helpful in the management of autoimmune diseases such as Multiple Sclerosis and some forms of arthritis.
It is always seductive to solve our problems by just taking a pill. There are many strategies for improving pineal function and melatonin levels before resorting to supplementation:
Melatonin Supplementation:
Episodic treatment may be useful in the following situations:
Regular Treatment may be indicated in individuals with the following conditions:
Dosing Options:
Dosing Strategies:
Start low and escalate the dose slowly. Effects that suggest that the dose is excessive for you include excessive sleepiness in the early morning hours, day time sedation, hyperirritability, excessively vivid dreaming. I suggest starting as low as 0.5 mgs each night and escalating the dose by 0.5-1.0 mgs every three to five days. Keep a diary so you can track the effects. When there is a need to reduce the dose do it slowly by 0.5-1.0 mg increments.